ArticleClinical cardiology2025
A Clinical Study of Precision Chemoablation for Hypertrophic Obstructive Cardiomyopathy Without Large Interventricular Septal Branches.
Article in Clinical cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aims to evaluate the clinical efficacy and safety of ultrasound-guided percutaneous septal precision chemical ablation in the treatment of hypertrophic obstructive cardiomyopathy (HOCM).
methodsFrom December 2020 to July 2024, 27 patients with HOCM without large target septal branches (diffuse multiple branches, all less than 1 mm in diameter) were enrolled and underwent ultrasound-guided percutaneous septal chemical ablation. Intraoperative left ventricular outflow tract gradient (LVOTG), postoperative cardiac troponin I (cTnI), complications, and changes in the 36-Item Short Form Survey (SF-36) score, New York Heart Association (NYHA) functional classification and echocardiography parameters in 1 year post-PTSMA were monitored and analyzed.
resultsImmediate postoperative LVOTG values monitored by catheter and echocardiography were both significantly decreased (both p < 0.05) in the 27 patients, whereas the cTnI level was increased after PTSMA treatment (p < 0.05). One patient developed transient complete right bundle branch block during the procedure. At the 1-year follow-up, these patients showed significantly increased scores in all the eight domains of the SF-36 scale, and markedly improvement in echocardiography-based LVOTG value (p < 0.05) and NYHA functional classification (p < 0.05). However, no significant change were observed in the mean interventricular septal thickness (IVSTh) and left ventricular ejection fraction (LVEF) before and after operation (p > 0.05).
conclusionUltrasound-guided precision PTSMA with gelatin sponge is a safe and effective treatment approach for HOCM patients, which can reduce the left ventricular outflow tract obstruction and greatly improve the life quality of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.